Eczema laboratory findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1], Associate Editor(s)-in-Chief: Edzel Lorraine Co, D.M.D., M.D.

Overview

Doing a routine laboratory testing for eczema is not mandatory. Although an elevated Level of IgE is associated with eczema, it is not specific to this disease. Several other medical conditions manifest with elevated IgE levels such as allergy, parasitic infections, autoimmune diseases, and certain carcinomas. ^[1] ^[2] ^[3] ^[4]

Laboratory Findings

An elevated IgE level can also be associated with eczema.
Some in vitro skin tests may be done when suspecting an eczema. ^[5] ^[6]

References

↑ Eichenfield LF, Tom WL, Chamlin SL, Feldman SR, Hanifin JM, Simpson EL; et al. (2014). “Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis”. J Am Acad Dermatol. 70 (2): 338–51. doi:10.1016/j.jaad.2013.10.010. PMC 4410183. PMID 24290431.
↑ Kabashima K (2013). “New concept of the pathogenesis of atopic dermatitis: interplay among the barrier, allergy, and pruritus as a trinity”. J Dermatol Sci. 70 (1): 3–11. doi:10.1016/j.jdermsci.2013.02.001. PMID 23473856.
↑ Murat-Susić S, Lipozencić J, Zizić V, Husar K, Marinović B (2006). “Serum eosinophil cationic protein in children with atopic dermatitis”. Int J Dermatol. 45 (10): 1156–60. doi:10.1111/j.1365-4632.2006.02865.x. PMID 17040428.
↑ Schulte-Herbrüggen O, Fölster-Holst R, von Elstermann M, Augustin M, Hellweg R (2007). “Clinical relevance of nerve growth factor serum levels in patients with atopic dermatitis and psoriasis”. Int Arch Allergy Immunol. 144 (3): 211–6. doi:10.1159/000103994. PMID 17579279.
↑ Ring J, Alomar A, Bieber T, Deleuran M, Fink-Wagner A, Gelmetti C; et al. (2012). “Guidelines for treatment of atopic eczema (atopic dermatitis) part I.” J Eur Acad Dermatol Venereol. 26 (8): 1045–60. doi:10.1111/j.1468-3083.2012.04635.x. PMID 22805051.
↑ Schneider L, Tilles S, Lio P, Boguniewicz M, Beck L, LeBovidge J; et al. (2013). “Atopic dermatitis: a practice parameter update 2012”. J Allergy Clin Immunol. 131 (2): 295-9.e1-27. doi:10.1016/j.jaci.2012.12.672. PMID 23374261.

[pmid24290431-1] Eichenfield LF, Tom WL, Chamlin SL, Feldman SR, Hanifin JM, Simpson EL; et al. (2014). “Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis”. J Am Acad Dermatol. 70 (2): 338–51. doi:10.1016/j.jaad.2013.10.010. PMC 4410183. PMID 24290431.

[pmid23473856-2] Kabashima K (2013). “New concept of the pathogenesis of atopic dermatitis: interplay among the barrier, allergy, and pruritus as a trinity”. J Dermatol Sci. 70 (1): 3–11. doi:10.1016/j.jdermsci.2013.02.001. PMID 23473856.

[pmid17040428-3] Murat-Susić S, Lipozencić J, Zizić V, Husar K, Marinović B (2006). “Serum eosinophil cationic protein in children with atopic dermatitis”. Int J Dermatol. 45 (10): 1156–60. doi:10.1111/j.1365-4632.2006.02865.x. PMID 17040428.

[pmid17579279-4] Schulte-Herbrüggen O, Fölster-Holst R, von Elstermann M, Augustin M, Hellweg R (2007). “Clinical relevance of nerve growth factor serum levels in patients with atopic dermatitis and psoriasis”. Int Arch Allergy Immunol. 144 (3): 211–6. doi:10.1159/000103994. PMID 17579279.

[pmid22805051-5] Ring J, Alomar A, Bieber T, Deleuran M, Fink-Wagner A, Gelmetti C; et al. (2012). “Guidelines for treatment of atopic eczema (atopic dermatitis) part I.” J Eur Acad Dermatol Venereol. 26 (8): 1045–60. doi:10.1111/j.1468-3083.2012.04635.x. PMID 22805051.

[pmid23374261-6] Schneider L, Tilles S, Lio P, Boguniewicz M, Beck L, LeBovidge J; et al. (2013). “Atopic dermatitis: a practice parameter update 2012”. J Allergy Clin Immunol. 131 (2): 295-9.e1-27. doi:10.1016/j.jaci.2012.12.672. PMID 23374261.

[1]

[2]

[3]

[4]

[5]

[6]

Eczema laboratory findings

Overview

Laboratory Findings

References

Looking for the patient version?